Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep
- PMID: 38467891
- DOI: 10.1007/s00213-024-06572-2
Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep
Abstract
Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properties in preclinical and clinical studies. Previous research from our group showed that ibogaine suppresses sleep and produces an altered wakefulness state, which resembles natural REM sleep. However, after systemic administration, ibogaine is rapidly metabolized to noribogaine, which also shows antiaddictive effects but with a distinct pharmacological profile, making this drug a promising therapeutic candidate. Therefore, we still ignore whether the sleep/wake alterations depend on ibogaine or its principal metabolite noribogaine. To answer this question, we conducted polysomnographic recordings in rats following the administration of pure noribogaine. Our results show that noribogaine promotes wakefulness while reducing slow-wave sleep and blocking REM sleep, similar to our previous results reported for ibogaine administration. Thus, we shed new evidence on the mechanisms by which iboga alkaloids work in the brain.
Keywords: EEG; Ibogaine; Psychedelics; REM sleep; Slow-wave sleep.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.Front Pharmacol. 2018 Apr 27;9:374. doi: 10.3389/fphar.2018.00374. eCollection 2018. Front Pharmacol. 2018. PMID: 29755349 Free PMC article.
-
A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats.ACS Chem Neurosci. 2020 Jun 3;11(11):1661-1672. doi: 10.1021/acschemneuro.0c00152. Epub 2020 May 18. ACS Chem Neurosci. 2020. PMID: 32330007
-
Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism.Pharmacol Biochem Behav. 1997 Aug;57(4):809-15. doi: 10.1016/s0091-3057(96)00383-8. Pharmacol Biochem Behav. 1997. PMID: 9259010
-
Mechanisms of antiaddictive actions of ibogaine.Ann N Y Acad Sci. 1998 May 30;844:214-26. Ann N Y Acad Sci. 1998. PMID: 9668680 Review.
-
How toxic is ibogaine?Clin Toxicol (Phila). 2016;54(4):297-302. doi: 10.3109/15563650.2016.1138226. Epub 2016 Jan 25. Clin Toxicol (Phila). 2016. PMID: 26807959 Review.
Cited by
-
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Adv Sci (Weinh). 2025 Apr;12(15):e2413786. doi: 10.1002/advs.202413786. Epub 2025 Mar 20. Adv Sci (Weinh). 2025. PMID: 40112231 Free PMC article. Review.
References
-
- Alper KR, Lotsof HS, Frenken GM et al (1999) Treatment of acute opioid withdrawal with ibogaine. Am J Addict 8:234–242 - PubMed
-
- Arıkan MK, Uysal Ö, Gıca Ş, Orhan Ö, İlhan R, Esmeray MT, Bakay H, Metin B, Pogarell O, Turan Ş (2023) REM parameters in drug-free major depressive disorder: a systematic review and meta-analysis. Sleep Med Rev 73:101876 - PubMed
-
- Bagal AA, Hough LB, Nalwalk JW, Glick SD (1996) Modulation of morphine-induced antinociception by ibogaine and noribogaine. Brain Res 741:258–262 - PubMed
-
- Baumann MH, Pablo J, Ali SF et al (2001a) Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. Alkaloids Chem Biol 56:79–113 - PubMed
-
- Baumann MH, Rothman RB, Pablo JP, Mash DC (2001b) In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 297:531–539 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources